NCT04874480View on ClinicalTrials.gov

Tegavivint for the Treatment of Relapsed or Refractory Leukemia

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

9

Participants

Timeline

Start Date

September 27, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Recurrent LeukemiaRefractory Leukemia

Interventions

DRUG

Decitabine

Given IV

DRUG

Tegavivint

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER